Alere Inc. (ALR): Carol R Goldberg , director of Alere Inc. sold 110 shares on Jan 13, 2015. The Insider selling transaction was disclosed on Apr 12, 2016 to the Securities and Exchange Commission. The shares were sold at $39.46 per share for a total value of $4,340.60.
Company has been under the radar of several Street Analysts.Alere Inc is Downgraded by Goldman to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Feb 2, 2016.Alere Inc is Downgraded by Jefferies to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Feb 2, 2016.Alere Inc is Downgraded by Raymond James to Mkt Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Feb 2, 2016.Alere Inc is Downgraded by Canaccord Genuity to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Feb 2, 2016.
Currently the company Insiders own 1.93% of Alere Inc shares according to the proxy statements.Institutional Investors own 99.55% of Alere Inc shares.During last six month period, the net percent change held by insiders has seen a change of 39.51%.
Shares of Alere Inc (ALR) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.23 points or -0.46% at $50.05 with 8,46,173 shares getting traded. Post opening the session at $50.47, the shares hit an intraday low of $50.01 and an intraday high of $50.47 and the price vacillated in this range throughout the day. The company has a market cap of $4,317 M and the number of outstanding shares has been calculated to be 8,62,56,820 shares. The 52-week high of Alere Inc is $55.99 and the 52-week low is $31.96.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics patient self-testing consumer diagnostics and corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time deliver care and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD) its 50/50 joint venture with The Procter & Gamble Company (P&G).